Source-grounded facts extracted from Xenetic Biosciences, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Xenetic Biosciences, Inc. reported the three months ended March 31, 2026 results: revenue approximately $0.8 million, net income approximately $0.5 million.
“Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company’s sublicense agreement with Takeda Pharmaceuticals Co. Ltd.”
Xenetic Biosciences, Inc. reported the year ended December 31, 2025 results: revenue $3.0 million, net income approximately $2.7 million.
“investment in the Company’s most promising scientific programs. Royalty revenue from the Company’s sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025 from $2.5 million for the year ended December 31, 2024 primarily due to royalty payments received from certain countries. Research and”
Xenetic Biosciences, Inc. engaged CBIZ CPAs P.C. as its auditor.
“On April 9, 2025, with the approval of the Company’s Audit Committee, CBIZ was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Marcum LLP resigned as auditor of Xenetic Biosciences, Inc..
“On April 8, 2025, Xenetic Biosciences, Inc. (the "Company") was notified by Marcum that Marcum resigned as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s Audit Committee approved the resignation.”
Adam Logal departed as member of the board of directors at Xenetic Biosciences, Inc..
“On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders.”
James E. Callaway departed as member of the board of directors at Xenetic Biosciences, Inc..
“On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders.”
Curtis Lockshin departed as Chief Scientific Officer at Xenetic Biosciences, Inc..
“and Curtis Lockshin, the Company’s former Chief Scientific Officer”
Jeffrey F. Eisenberg departed as Chief Executive Officer at Xenetic Biosciences, Inc..
“the Company entered into a confidential separation agreement and general release with each of and Jeffrey F. Eisenberg, the Company’s former Chief Executive Officer”
James F. Parslow was appointed as Interim Chief Executive Officer at Xenetic Biosciences, Inc..
“the Board of Directors of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.”
James F. Parslow was appointed as Interim Chief Executive Officer at Xenetic Biosciences, Inc..
“On May 16, 2024, the Board of Directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.”
Dr. Curtis Lockshin departed as Chief Scientific Officer at Xenetic Biosciences, Inc..
“In addition on May 16, 2024, the Company and Dr. Curtis Lockshin mutually agreed that Dr. Lockshin would step down as the Chief Scientific Officer of the Company, effective immediately.”
Jeffrey F. Eisenberg resigned as Director at Xenetic Biosciences, Inc..
“and in connection therewith, Mr. Eisenberg resigned as a director of the Company and all of its subsidiaries, as applicable.”
Jeffrey F. Eisenberg departed as Chief Executive Officer at Xenetic Biosciences, Inc..
“On May 16, 2024, the Company and Jeffrey F. Eisenberg mutually agreed that Mr. Eisenberg would step down as the Chief Executive Officer of the Company, effective immediately”
Xenetic Biosciences, Inc. reported first quarter of 2024 results: net income Net loss for the quarter ended March 31, 2024 was approximately $1.2 million..
“On May 10, 2024, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended March 31, 2024 and providing a business update.”
Xenetic Biosciences, Inc. reported the year ended December 31, 2023 results: net income approximately $4.1 million.
“Net loss for the year ended December 31, 2023 was approximately $4.1 million.”
Xenetic Biosciences, Inc. shareholders rejected Advisory vote on named executive officer compensation at the 2023-12-06 meeting.
“The Company’s stockholders voted upon, on a non-binding, advisory basis, the Company’s named executive officer compensation. The proposal did not receive an affirmative vote of a majority of the shares cast.”
Xenetic Biosciences, Inc. shareholders approved Ratification of selection of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-06 meeting.
“The Company’s stockholders voted upon and approved the ratification of the selection of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.”
Xenetic Biosciences, Inc. shareholders approved Election of nine nominees to the Board of Directors at the 2023-12-06 meeting.
“The Company’s stockholders approved the election of the following nine nominees with each director receiving votes as follows:”
Xenetic Biosciences, Inc. reported financial results for the three months ended September 30, 2023.
“On November 10, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended September 30, 2023”
Xenetic Biosciences, Inc. reported financial results for second quarter of 2023.
“On August 11, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended June 30, 2023 and providing a corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and hereby incorporated in this Item 2.02 by reference.”
Xenetic Biosciences, Inc.: Filed a Certificate of Change to effect a one-for-ten reverse stock split, reducing authorized common stock from 100,000,000 to 10,000,000 shares (effective 2023-05-11).
“on May 11, 2023, Xenetic Biosciences, Inc. (the “Company”) filed a Certificate of Change to the Company’s Articles of Incorporation (the “Change”) with the Secretary of State of the State of Nevada to effect a one-for-ten reverse stock split of its authorized, issued and outstanding common stock”
Xenetic Biosciences, Inc. reported three months ended March 31, 2023 results: net income approximately $0.9 million.
“Net loss for the quarter ended March 31, 2023 was approximately $0.9 million.”
Xenetic Biosciences, Inc. reported the full year 2022 results: net income Net loss for the year ended December 31, 2022 was approximately $6.6 million..
“On March 23, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the year ended December 31, 2022 and providing a corporate update.”
Xenetic Biosciences, Inc. shareholders approved Amendment to increase authorized common stock from 50,000,000 to 100,000,000 shares at the 2022-12-21 meeting.
“Proposal Four : The Company’s stockholders voted upon and approved and adopted an amendment to the Company’s Articles of Incorporation to increase the authorized number of shares of the Company’s common stock from 50,000,000 shares to 100,000,000 shares. The votes on this proposal were as follows: For Against Abstained Broker Non-Votes 7,204,486 1,131,034 110,245 –”
Xenetic Biosciences, Inc. shareholders approved Advisory vote on named executive officer compensation at the 2022-12-07 meeting.
“3. The Company’s stockholders voted upon and approved, on a non-binding, advisory basis, the Company’s named executive officer compensation. The votes on this proposal were as follows: For Against Abstained Broker Non-Votes 4,231,759 699,669 65,677 2,866,140”
Xenetic Biosciences, Inc. shareholders approved Ratification of Marcum LLP as independent registered public accounting firm at the 2022-12-07 meeting.
“2. The Company’s stockholders voted upon and approved the ratification of the selection of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. The votes on this proposal were as follows: For Against Abstained Broker Non-Votes 7,370,441 434,234 58,570 -”
Xenetic Biosciences, Inc. shareholders approved Election of seven director nominees at the 2022-12-07 meeting.
“1. The Company’s stockholders approved the election of the following seven nominees with each director receiving votes as follows: Name For Withheld Broker Non-Votes Dr. Grigory Borisenko 4,262,295 734,810 2,866,140 Dr. James Callaway 3,615,669 1,381,436 2,866,140 Mr. Firdaus Jal Dastoor 4,245,854 751,251 2,866,140 Mr. Jeffrey Eisenberg 4,271,238 725,867 2,866,140 Dr. Roger Kornberg 3,607,135 1,389,970 2,866,140 Mr. Adam Logal 4,253,923 743,182 2,866,140 Mr. Alexey Vinogradov 4,273,562 723,543 2,866,140”
Xenetic Biosciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“December 1, 2022, the Company received a letter from Nasdaq informing it that although the Company’s common stock has not regained compliance with the minimum $1.00 bid price per share requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until May 29, 2023, to regain compliance. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requireme”
Xenetic Biosciences, Inc. reported the three months ended September 30, 2022 results: net income approximately $0.8 million.
“Net loss for the quarter ended September 30, 2022 was approximately $0.8 million.”
Dmitry Genkin resigned as member of the Board of Directors at Xenetic Biosciences, Inc..
“On July 15, 2021, Dr. Dmitry Genkin resigned as a member of the Board of Directors of Xenetic Biosciences, Inc.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.